Mosqivac: Bharat Biotech cuts malaria vaccine price by 40%
Why in the news
Hyderabad-based Bharat Biotech announced on 23 October 2026 that it will lower the price of its malaria vaccine Mosqivac by about 40% for Gavi-supported programmes.
Key facts
- Vaccine: RTS,S/AS01, developed by GSK and now produced by Bharat Biotech under a technology transfer; marketed as Mosqivac.
- New price: €5.50 per dose from early 2027, down from €9.30.
- Roles: UNICEF will execute the agreement and Gavi, the Vaccine Alliance will finance it.
- Impact: savings of about $50 million for 2027-2029, allowing protection of an additional one million children.
- Investment: Bharat Biotech and GSK have put $200 million into capacity, product development and technology transfer.
- Efficacy: a full four-dose course cuts cases by about 75% when given seasonally in high-transmission areas.
Malaria at a glance (2024)
| Indicator | Figure |
|---|---|
| Global cases | About 282 million |
| Global deaths | About 610,000 |
| Africa’s share of cases and deaths | Up to 95% |
About RTS,S
RTS,S was the first malaria vaccine recommended by WHO, in 2021. Gavi-funded malaria vaccination is now part of routine immunisation in 25 African countries. In June 2025, GSK and Bharat Biotech had pledged to bring the price below $5 per dose by 2028 as part of commitments to Gavi’s 2026-2030 replenishment.
Exam angle
- Mosqivac = RTS,S/AS01; maker Bharat Biotech; developer GSK.
- Price: €9.30 to €5.50 per dose (about 40% cut) from 2027.
- WHO recommendation year: 2021.